Skip to content
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Contact Us
Schwab Client Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Connect Biopharma Holdings Limited - Ordinary Shares
(NQ:
CNTB
)
0.9270
-0.0530 (-5.41%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Connect Biopharma Holdings Limited - Ordinary Shares
< Previous
1
2
3
Next >
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
September 30, 2026
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation
September 15, 2026
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 03, 2026
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
June 17, 2026
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
May 12, 2026
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis
April 23, 2026
Expect to report topline data from both studies mid-2026
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
April 07, 2026
Via
ACCESS Newswire
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
March 31, 2026
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Announces $20.2 Million Private Placement Financing
March 30, 2026
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
March 30, 2026
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD
March 30, 2026
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting
March 10, 2026
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference
March 03, 2026
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 19, 2026
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026
January 12, 2026
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference
November 24, 2025
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma and Bimergen Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
November 14, 2025
Via
ACCESS Newswire
Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update
November 12, 2025
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3
October 30, 2025
Via
ACCESS Newswire
Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025
September 29, 2025
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025
September 04, 2025
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq
September 03, 2025
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma to Present at Two Upcoming Investor Conferences in September
August 27, 2025
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide
August 14, 2025
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update
August 13, 2025
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors
July 22, 2025
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq
July 21, 2025
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference
July 18, 2025
From
Connect Biopharma Holdings Limited
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
